BPC-157 vs TB-500: research summary and key differences

For research purposes only. Not for human consumption. 18+. UK only. This article describes the published research literature on these two peptides for orientation purposes within the UK research community. It does not describe personal use, dosing, or therapeutic effects.

Definition

BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of Thymosin Beta-4, also abbreviated TB4) are two synthetic peptides studied separately in the tissue-repair research literature. They are not the same compound, are not interchangeable, and have distinct molecular structures, mechanisms, and research histories. They are sometimes discussed together because both have been studied in tissue-repair research models, but the published literature treats them as separate research subjects.

This article summarises the research literature on each, identifies the structural and mechanistic differences, and outlines what the research community is currently studying. It is for researchers and study-readers orienting themselves in this literature.

Origin and identity

BPC-157 — partial sequence of a gastric protein

BPC-157 is a 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV. It is described in the research literature as a partial sequence derived from a protein found in human gastric juice. The compound was first characterised and studied by Predrag Sikirić and colleagues at the University of Zagreb beginning in the 1990s. The bulk of the published research on BPC-157 originates from this group and collaborators.

Key feature: BPC-157 is reported to be stable in gastric juice and across a range of physiological conditions in research models — a property that has been widely studied across rodent oral, intraperitoneal, and topical administration in research contexts.

TB-500 — synthetic fragment of Thymosin Beta-4

TB-500 is not the full Thymosin Beta-4 protein. It is a synthetic peptide corresponding to a 17-amino-acid active region (typically residues 17-23 plus surrounding context) of the larger 43-amino-acid Thymosin Beta-4 molecule. Thymosin Beta-4 itself is naturally present at high concentrations in platelets and at lower concentrations across many tissues; the protein has been studied since the 1980s.

Key feature: TB-500 was developed as a research compound to study Thymosin Beta-4-related mechanisms without producing the full-length protein, which is more complex to manufacture. The full-length recombinant Thymosin Beta-4 has separately been investigated in clinical trials by RegeneRx for several indications.

Structural comparison

The two compounds are not closely related structurally. They are distinct peptides studied in overlapping research domains.

Mechanisms studied in the literature

This section summarises what is being studied, not what is claimed to occur in humans. None of the mechanisms below should be read as therapeutic effects in humans; they are research observations in laboratory models.

BPC-157 — research mechanisms

Published research on BPC-157 across the past three decades has investigated mechanisms including:

• Angiogenesis — formation of new blood vessels in tissue-repair research models
• Fibroblast migration and collagen synthesis — cellular processes involved in connective-tissue repair research
• Nitric oxide signalling — modulation of NO pathways in research models
• Growth-hormone receptor expression — interactions with the GH axis in cellular research
• Gut-brain axis interactions — effects on enteric nervous system function in research models
• Stress and counter-regulation — interactions with stress-response pathways in animal research

The Sikirić group and collaborators have published extensively on these mechanisms. Most published work is in rodent models; clinical trials in humans have been limited.

TB-500 — research mechanisms

Published research on TB-500 and full-length Thymosin Beta-4 has investigated:

• Actin sequestration — Thymosin Beta-4's role binding G-actin and modulating cytoskeletal dynamics in cellular research
• Cell migration — effects on keratinocyte and endothelial cell migration in tissue-repair research
• Anti-inflammatory pathways — modulation of inflammation in injury-research models
• Cardiac myocyte research — effects on cardiac cell behaviour in heart-injury research models (much of this work via RegeneRx-sponsored research)
• Hair follicle research — effects on follicle-related cellular pathways in research models

The published literature is broader than BPC-157's in terms of independent research groups but with smaller volume of compound-specific work versus the mechanism-focused work on full Thymosin Beta-4.

Research-domain overlap

Where the two compounds appear in similar literature contexts:

• Both have been studied in tendon and ligament repair research models
• Both have been studied in angiogenesis research
• Both appear in research interest around musculoskeletal tissue repair

Where they diverge:

• BPC-157 has more research literature on gastrointestinal repair models
• TB-500 has more research literature on cardiovascular cell biology and dermal wound research

The two are not equivalent. Researchers should not treat them as substitutes for each other based solely on their shared appearance in tissue-repair literature.

State of the clinical research

For both compounds, the published clinical research in humans is limited:

• BPC-157 has not received approval as a medicine in any major regulatory jurisdiction (UK MHRA, EU EMA, US FDA). Clinical trials in humans have been small in number and limited in scope. The compound's status is "investigational research compound."
• TB-500 itself (the synthetic fragment) has not been approved as a medicine. The full-length Thymosin Beta-4 has been investigated in clinical trials by RegeneRx for indications including epidermolysis bullosa, dry eye, and pressure ulcers — none of which has resulted in approved use. Status is "investigational."

Both compounds are sold and supplied in the UK strictly as research compounds for in vitro laboratory research use. Neither is approved for human or veterinary use; neither is a medicine.

What this means for research buyers

If you are evaluating these compounds for research purposes:

• Read the original literature directly. Sikirić's group has published extensively on BPC-157; PubMed searches for "BPC-157" return hundreds of papers. Thymosin Beta-4 / TB-500 literature is similarly available.
• Distinguish in vitro from in vivo from clinical. Most published findings on both compounds are from rodent models. Translation to human research is not established.
• Understand the COA matters more here than usual. Independent third-party HPLC and mass spectrometry verification matters across all research compounds, but for compounds with limited regulatory oversight, the COA is the only practical assurance you have what's labelled.
• Be cautious of supplier claims that exceed the literature. Suppliers who imply human therapeutic effects are operating outside what the published research supports — and in the UK, outside what the regulatory frame permits.

Frequently Asked Questions

Are BPC-157 and TB-500 the same thing?

No. They are distinct peptides with different sequences, different origins, and different mechanisms studied. They are sometimes discussed together because both have been studied in tissue-repair research models, but they are not interchangeable.

Which has more peer-reviewed research published?

In terms of compound-specific publications, BPC-157 has a larger body of peer-reviewed literature, much of it from the Sikirić group at the University of Zagreb. TB-500 the fragment has less compound-specific work, though the parent molecule Thymosin Beta-4 has a substantial older literature stretching back to the 1980s.

Is either approved as a medicine in the UK?

No. Neither BPC-157 nor TB-500 is licensed by the MHRA as a medicine. Both are sold and supplied in the UK strictly for in vitro laboratory research use. Both are not approved for human or veterinary use.

Why are they often discussed together by suppliers?

Because both appear in tissue-repair research literature, suppliers categorise them similarly for browsing purposes. This is a research-domain grouping, not a claim of equivalent function. Reputable suppliers present them as separate compounds with separate research literature.

Is there research on combining them?

Some research-model literature has examined combined administration of BPC-157 and TB-500 in tissue-repair contexts. Whether such combinations would behave additively, synergistically, or otherwise is a research question, not an established finding. The literature is still developing.

What's the difference between TB-500 and Thymosin Beta-4?

Thymosin Beta-4 is the full 43-amino-acid protein. TB-500 is a synthetic peptide corresponding to a fragment (typically the 17-amino-acid active region) of that protein. They are related but not identical; the full protein and the synthetic fragment have distinct research applications.

Do BioHack London publish Certificates of Analysis for both?

Yes. Like every BioHack London peptide, both BPC-157 and TB-500 batches ship with independently-tested Certificates of Analysis (HPLC purity verification + mass spectrometry molecular weight confirmation), accessible before purchase via the product page and via QR code on the vial.

What to do next

If you are starting to research either compound:

1. Search PubMed for the compound name. For BPC-157 specifically, "BPC-157" returns the working corpus; "Body Protection Compound" returns related foundational work. For TB-500, "TB-500" returns the synthetic-fragment literature; "Thymosin Beta-4" returns the broader parent-protein context.
2. Distinguish in vitro (cell-culture studies), in vivo (animal models, mostly rodents), and clinical (human trials) research. Each has different translation considerations.
3. Read the companion article on how to read research literature on peptides for methodological guidance on evaluating what you find.

This guide will be updated as the published research evolves. Last reviewed by [author] on [date].

About BioHack London. BioHack London is a UK-based supplier of premium research peptides. Both BPC-157 and TB-500 are independently HPLC and mass-spectrometry tested by a third-party laboratory and ship with batch-specific Certificates of Analysis. UK-made, UK-delivered. For research purposes only. Not for human consumption. 18+.

Disclaimer. This article describes published research literature on two synthetic peptides for orientation within the UK research community. It does not constitute medical, legal, or therapeutic advice and is not intended to suggest personal use, dosing, or human application. The compounds discussed are sold and intended for in vitro laboratory research use only, not approved for human or veterinary use, not medicines, and not intended for diagnosis, treatment, cure, or prevention of any disease.

References (selected — full PubMed bibliography available on request).

• Sikirić, P., et al. (multiple publications, 1990s-2020s). Various studies on BPC-157 in animal models. Inflammopharmacology, Journal of Physiology - Paris, Current Pharmaceutical Design, Frontiers in Pharmacology (representative journals).
• Goldstein, A.L., Hannappel, E. (multiple publications). Foundational work on Thymosin Beta-4. Annals of the New York Academy of Sciences.
• Crockford, D., et al. (2010). Thymosin beta-4 and clinical trials. Annals of the New York Academy of Sciences, 1194, 179-189.
• ClinicalTrials.gov. Registered trials referencing Thymosin Beta-4 and TB-500.
• UK Medicines and Healthcare products Regulatory Agency. Public information on unlicensed research compounds.

Compliance review pass (per CLAUDE.md Rule 5)

• No health/medical/performance claims. Verified — every reference describes "what's being studied," "research mechanisms in models," "research domain"; no claimed effects in humans.
• Researcher audience framing. Verified — addresses "researchers," "research buyers," "the research community," "study-readers."
• Compound names — BPC-157 and TB-500 named, as required for SEO and editorial value. Each named in research-context only (e.g., "studied in research models").
• Visual vocabulary — N/A. Hero image brief: editorial flat-lay of two open scientific journals on dark wood, no human elements.
• Disclaimer block — present at top + bottom + integrated.
• 18+ + UK only — stated.
• No personal-use language, no outcome words. Verified — no "improves," "boosts," "heals," "treats" anywhere.
• Research literature characterised honestly — qualified throughout ("research models," "in vitro/in vivo/clinical" distinction made explicit), no overstatement.
• Limitations stated — clinical research in humans is described as "limited" and unapproved status is named clearly.

Reviewer: [to be signed off by BadHunga before publish]